Chardan Capital analyst Gbola Amusa reiterated a Buy rating on Meiragtx Holdings Plc (MGTX) today and set a price target of $40. The company’s shares closed yesterday at $23.07, close to its 52-week high of $24.
According to TipRanks.com, Amusa is a 5-star analyst with an average return of 17.9% and a 51.4% success rate. Amusa covers the Healthcare sector, focusing on stocks such as Nightstar Therapeutics Limited, Iovance Biotherapeutics Inc, and Logicbio Therapeutics Inc.
Meiragtx Holdings Plc has an analyst consensus of Moderate Buy, with a price target consensus of $35, a 51.7% upside from current levels. In a report issued on May 15, Barclays also maintained a Buy rating on the stock with a $30 price target.
See today’s analyst top recommended stocks >>
Based on Meiragtx Holdings Plc’s latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $21.06 million. In comparison, last year the company had a GAAP net loss of $16.4 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
MeiraGTx Holdings Plc is a clinical-stage biotech company, which engages in the development of novel gene therapy treatments. It operates through the United States and United Kingdom geographical segments. Its pipeline includes AAV-CNGB3, AAV-CNGA3, AAV-RPE65, AAV-RPGR, AAV-AQP1, and AAV-UPF1.
